Anebulo’s ANEB-001 Shows Promise in Treating Acute Cannabinoid Intoxication

Austin, Texas-based Anebulo Pharmaceuticals said that its investigational small molecule cannabinoid receptor antagonist, ANEB-001, has shown promise in treating acute cannabinoid intoxication.

In an ongoing phase 2 study, 60 participants were randomized to evaluate a single dose of ANEB-001 in subjects challenged with delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis.

The treatment significantly reduced symptoms of acute cannabinoid intoxication in the group who received the treatment compared with those given a placebo, the company said.

The company expects to file an Investigational New Drug application (IND) with the FDA by the end of 2022. Currently, there are no FDA-approved therapies for the indication.